To the Editor.
—The recent report by Buchholz and Kariya1 again emphasized the now well-established fact that parkinsonism is a potential complication of long-term metoclopramide therapy.2,3 Domperidone, a peripheral dopaminergic blocking agent, has been documented to have little or no effect on central dopamine receptors4 and has been reported to be safe in treating Parkinson's disease.5 The drug is now undergoing clinical trials in the United States and Canada to assess its efficacy and safety in controlling levodopa- and dopamine agonist-induced gastric upset in patients with Parkinson's disease. Its protective effect is thought to be on the chemoreceptor trigger zone of the area postrema which lies outside the blood-brain barrier.
Report of a Case.
—We had a case of metoclopramide-induced parkinsonism that resolved with domperidone therapy. A 59-year-old diabetic woman had progressively worsening nausea and vomiting from impaired gastric emptying. Metoclopramide, 20 mg daily, gave complete
Grimes JD, Magner PO. Safety of Domperidone in Metoclopramide-Induced Parkinsonism. Arch Neurol. 1984;41(4):363–364. doi:10.1001/archneur.1984.04050160025009
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: